Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2016 Jun;16(6):653-60. doi: 10.1586/14737140.2016.1170596. Epub 2016 Apr 8.

Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.

Author information

1
a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
2
b Department of Oncology , University of Turin, A.O.U. San Luigi Gonzaga , Orbassano , Italy.

Abstract

Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses of platinum compounds leading to increased tolerability. Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised medicine, are being investigated. Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients.

KEYWORDS:

Carboplatin; NSCLC; chemotherapy; cisplatin; first-line; metastatic; non-small-cell lung cancer; treatment

PMID:
27010977
DOI:
10.1586/14737140.2016.1170596
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for University of Turin Instituional Repository AperTO
Loading ...
Support Center